vida: extract claims from 2026-05-12-fda-glp1-telehealth-warning-letters-screening-gap

- Source: inbox/queue/2026-05-12-fda-glp1-telehealth-warning-letters-screening-gap.md
- Domain: health
- Claims: 2, Entities: 0
- Enrichments: 4
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/ai-telehealth-glp1-prescribing-commoditizes-at-scale-but-generates-systematic-safety-and-fraud-failures.md

@@ -31,3 +31,10 @@ BMI 16 anorexia patient acquired GLP-1 online by lying about weight. Most patien
 **Source:** NBC News 2024-08-15
 
 NBC News notes 'greater telehealth vs. traditional oversight risk' for ED development in GLP-1 prescribing, suggesting remote prescribing may lack the clinical assessment needed to detect subclinical ED risk factors or monitor for emerging restriction patterns.
+
+
+## Extending Evidence
+
+**Source:** STAT News March 2026
+
+Network structure evidence: 30%+ of FDA-warned telehealth firms are affiliated with just 4 medical groups (Beluga Health, OpenLoop, MD Integrations, Telegra). Marketing and prescribing are separated—telehealth marketers make misleading claims while affiliated medical groups hold clinical responsibility. This concentration means regulatory action on 4 organizations could significantly change the market.

domains/health/glp1-atypical-anorexia-screening-gap-creates-invisible-high-risk-population.md

@@ -24,3 +24,10 @@ Dr. Kim Dennis identifies atypical anorexia as a specific high-risk population f
 **Source:** NPR Health, Feb 2026, clinical expert interviews
 
 Clinicians identify atypical anorexics as 'at high risk of being harmed' because they 'restrict food but maintain normal weight' making the condition invisible to doctors. Given GLP-1s are prescribed primarily for weight management, the typical candidate appearance overlaps with atypical AN presentation, creating a systematic detection failure. Nearly 10% of Americans meet clinical eating disorder criteria at some point, suggesting substantial overlap with GLP-1 candidate population.
+
+
+## Supporting Evidence
+
+**Source:** STAT News, ANAD guidance March 2026
+
+Telehealth platforms use online assessments reviewed by licensed clinicians without eating disorder specialist requirement, creating systematic failure to identify atypical presentations. ANAD guidance recommends physician + therapist + dietitian all versed in both GLP-1s and EDs, but actual practice lacks this infrastructure.

domains/health/glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge.md

@@ -123,3 +123,10 @@ Review recommends 'monthly check-ins with validated depression/suicidality tools
 **Source:** NPR Health, Feb 2026, interviews with Robyn Pashby (psychologist) and Samantha DeCaro (clinician)
 
 NPR reporting confirms that 'most patients receive NO evaluation for eating disorders before GLP-1 prescription' and that drugs are 'easy to obtain online, with little screening.' Psychologist Robyn Pashby notes the screening gap exists despite identified risk populations. This provides journalistic confirmation of the structural screening gap documented in clinical literature.
+
+
+## Extending Evidence
+
+**Source:** STAT News, DePaul JHLI April 2026
+
+DePaul JHLI analysis (April 2026) provides the mechanism: algorithmic telehealth assessments structurally cannot capture the psychological complexity needed to identify ED risk. Specifically, atypical anorexia nervosa (presenting in larger body) or non-purging bulimia nervosa may be misdiagnosed as binge eating disorder because algorithmic assessments lack the clinical specialist judgment required to distinguish these presentations.

domains/health/glp1-pre-treatment-eating-disorder-screening-recommended-not-required.md

@@ -11,7 +11,7 @@ sourced_from: health/2025-11-xx-mdpi-nutrients-glp1-appetite-eating-disorders-ps
 scope: structural
 sourcer: MDPI Nutrients
 supports: ["ai-telehealth-glp1-prescribing-commoditizes-at-scale-but-generates-systematic-safety-and-fraud-failures"]
-related: ["glp1-therapy-requires-nutritional-monitoring-infrastructure-but-92-percent-receive-no-dietitian-support", "glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-pre-treatment-eating-disorder-screening-recommended-not-required"]
+related: ["glp1-therapy-requires-nutritional-monitoring-infrastructure-but-92-percent-receive-no-dietitian-support", "glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-pre-treatment-eating-disorder-screening-recommended-not-required", "glp1-eating-disorder-screening-protocol-scoff-plus-history-plus-behavioral-assessment-recommended-for-pre-treatment-risk-stratification"]
 ---
 
 # Pre-treatment eating disorder screening is recommended by clinical reviews but not required by any professional guideline or regulatory body despite 4-7x elevated pharmacovigilance risk
@@ -52,3 +52,10 @@ The AgRP silencing mechanism strengthens the case for mandatory (not just recomm
 **Source:** PMC12694361 systematic review
 
 Systematic review establishes specific screening protocol components: SCOFF questionnaire administration, recent ED history review, assessment for compensatory behaviors, weight-suppression history evaluation. Also identifies treatment red flags: rapid weight loss, dizziness/syncope, escalating restriction, purging or laxative use. Positioned as clinical governance recommendation within 'multidisciplinary care' framework.
+
+
+## Supporting Evidence
+
+**Source:** STAT News, FDA warning letters March 2026
+
+FDA warning letters (70+ issued March 2026) target marketing claims but not prescribing practices. No mandatory protocol exists to screen for eating disorders prior to prescribing GLP-1s. ANAD provides professional society guidance but no regulatory enforcement mechanism exists.

domains/health/glp1-telehealth-network-concentration-creates-regulatory-leverage-point-with-four-medical-groups-serving-30-percent-of-warned-firms.md

@@ -0,0 +1,18 @@
+---
+type: claim
+domain: health
+description: "The telehealth GLP-1 prescribing market is not a diffuse regulatory problem but a concentrated network where 4 medical groups (Beluga Health, OpenLoop, MD Integrations, Telegra) serve at least 30% of FDA-warned telehealth companies"
+confidence: experimental
+source: STAT News analysis of FDA warning letters March 2026
+created: 2026-05-12
+title: GLP-1 telehealth network concentration creates regulatory leverage point with four medical groups serving 30+ percent of warned firms, making enforcement on concentrated infrastructure more effective than diffuse platform regulation
+agent: vida
+sourced_from: health/2026-05-12-fda-glp1-telehealth-warning-letters-screening-gap.md
+scope: structural
+sourcer: STAT News
+related: ["ai-telehealth-glp1-prescribing-commoditizes-at-scale-but-generates-systematic-safety-and-fraud-failures"]
+---
+
+# GLP-1 telehealth network concentration creates regulatory leverage point with four medical groups serving 30+ percent of warned firms, making enforcement on concentrated infrastructure more effective than diffuse platform regulation
+
+STAT News analysis of the 70+ FDA warning letters issued in March 2026 reveals that at least 30% of warned telehealth firms maintain public affiliations with just 4 nationwide medical groups: Beluga Health, OpenLoop, MD Integrations, and Telegra. This is an interconnected network structure, not isolated bad actors. The separation of functions is key: telehealth marketers make misleading claims while affiliated medical groups hold clinical responsibility for prescribing. This concentration means regulatory action on 4 organizations could significantly change the market—enforcement on the medical group infrastructure layer is more effective than trying to regulate hundreds of individual telehealth marketing platforms. The network structure also explains why FDA warning letters target marketing rather than prescribing: the companies receiving letters do NOT directly dispense, so FDA's marketing authority is the available regulatory tool. But the clinical gatekeeping happens at the medical group layer, which is where eating disorder screening gaps actually occur.

domains/health/glp1-telehealth-prescribing-scales-without-eating-disorder-screening-because-fda-regulates-marketing-not-prescribing-criteria.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: The regulatory gap between marketing oversight and clinical practice standards enables telehealth platforms to scale GLP-1 prescribing volume at software speed without the eating disorder screening infrastructure that professional societies recommend but regulators do not mandate
+confidence: experimental
+source: STAT News, FDA warning letters March 2026, ANAD guidance
+created: 2026-05-12
+title: GLP-1 telehealth prescribing scales without mandatory eating disorder screening because the FDA regulates marketing claims but not prescribing criteria, leaving 30+ million potential users without systematic eating disorder risk assessment
+agent: vida
+sourced_from: health/2026-05-12-fda-glp1-telehealth-warning-letters-screening-gap.md
+scope: structural
+sourcer: STAT News
+supports: ["glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge"]
+related: ["the-fda-now-separates-wellness-devices-from-medical-devices-based-on-claims-not-sensor-technology-enabling-health-insights-without-full-medical-device-classification", "ai-telehealth-glp1-prescribing-commoditizes-at-scale-but-generates-systematic-safety-and-fraud-failures", "glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge", "glp1-atypical-anorexia-screening-gap-creates-invisible-high-risk-population", "glp1-social-media-cosmetic-misuse-creates-eating-disorder-pathway", "glp1-eating-disorder-screening-lacks-reimbursement-infrastructure-despite-identified-risk-population", "glp1-eating-disorder-screening-protocol-scoff-plus-history-plus-behavioral-assessment-recommended-for-pre-treatment-risk-stratification"]
+---
+
+# GLP-1 telehealth prescribing scales without mandatory eating disorder screening because the FDA regulates marketing claims but not prescribing criteria, leaving 30+ million potential users without systematic eating disorder risk assessment
+
+The FDA issued 70+ warning letters to GLP-1 telehealth companies in March 2026, but these letters targeted misleading marketing claims (false FDA-approval statements, misleading manufacturing claims) rather than prescribing practices themselves. At least 30% of warned telehealth firms are affiliated with just 4 nationwide medical groups (Beluga Health, OpenLoop, MD Integrations, Telegra), creating a concentrated network structure where marketing and prescribing are separated—telehealth marketers make claims, affiliated medical groups hold clinical responsibility. The critical gap: no mandatory protocol exists to screen for eating disorders prior to prescribing GLP-1s. ANAD's guidance states 'We simply do not know if these medications will improve, worsen, or have no impact on eating disorder behaviors' and recommends pre-prescribing evaluation by physician + therapist + dietitian all versed in both GLP-1s and EDs. Actual telehealth practice: online assessment reviewed by licensed clinician, no eating disorder specialist required. The DePaul JHLI analysis (April 2026) identifies the mechanism: algorithmic telehealth assessments structurally cannot capture the psychological complexity needed to identify ED risk, particularly atypical presentations like atypical anorexia nervosa (presenting in larger body) or non-purging bulimia nervosa that may be misdiagnosed as binge eating disorder. This creates a systematic screening failure at scale—telehealth platforms process thousands of prescriptions per month without the clinical safeguard infrastructure the condition requires.

inbox/archive/health/2026-05-12-fda-glp1-telehealth-warning-letters-screening-gap.md

@@ -7,10 +7,13 @@ date: 2026-03-12
 domain: health
 secondary_domains: []
 format: article
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-12
 priority: medium
 tags: [GLP-1, telehealth, FDA, warning-letters, eating-disorders, screening, compounded-semaglutide, prescribing, governance]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content